A Phase 1, Double-Blind, Randomized, Placebo-controlled Leukapheresis Study to Obtain Lymphocytes for the Study of Immune Responses in Healthy Adult Volunteers in the U.S. who receive BCG Vaccination followed by Boosting with AERAS-402.
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2015
At a glance
- Drugs Tuberculosis vaccine (Primary) ; BCG vaccine
- Indications Tuberculosis
- Focus Pharmacodynamics
- Sponsors Aeras; Crucell
- 10 Jun 2017 Biomarkers information updated
- 01 Mar 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 21 Jan 2010 New trial record